MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, M. P.
Right arrow Articles by Nelson, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, M. P.
Right arrow Articles by Nelson, D. L.

Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines

MP Johnson, RJ Loncharich, M Baez and DL Nelson

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 26285.

Previous work has suggested that species differences in the structure- activity relationship for ergolines and tryptamines at the 5- hydroxytryptamine (5-HT)2A (formerly known as the 5-HT2) receptor are related to aliphatic substitution at the N1-position on the indole nucleus. The present work has confirmed these findings by examining the rat and human cloned 5-HT2A receptors. As previously found, N1- substitution of ergolines or tryptamines had no effect or increased affinity for the rat 5-HT2A receptor but decreased affinity for the human receptor. Also, the N1-unsubstituted analogues had higher affinity for the human 5-HT2A receptor, whereas the N1-alkyl analogues had a higher affinity for the rat receptor. By mutating the rat 5-HT2A receptor, the importance of the Ala/Ser242 species variation in amino acid sequence was examined in relation to this structure-activity relationship. Three mutations of the rat 5-HT2A receptor were made, i.e., A242S, A242V, and A242T. All three mutations resulted in functional (able to stimulate inositol phosphate hydrolysis) 5-HT2A receptors with high affinity for [3H]ketanserin and 1-(2,5-dimethoxy-4- [125I]iodophenyl)isopropylamine. The A242S mutation resulted in a pharmacological profile that was almost identical to that of the human 5-HT2A receptor but differed significantly from that of the wild-type rat receptor. This strongly suggests that the Ala/Ser242 species variation accounts for the differences in the structure-activity relationship. The A242V and A242T mutations resulted in differing but profound effects on affinity for the different ergolines and tryptamines. The results are discussed in terms of the importance of position 242 in the binding of these ligands to 5-HT2A receptors. In addition, arguments are presented that suggest that a hydrogen-bonding interaction occurs between the human 5-HT2A receptor at Ser242 and the N1-hydrogen of N1-unsubstituted ergolines and tryptamines and may serve as an important contact point in the receptor.

Volume 45, Issue 2, pp. 277-286, 02/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M. R. Braden and D. E. Nichols
Assessment of the Roles of Serines 5.43(239) and 5.46(242) for Binding and Potency of Agonist Ligands at the Human Serotonin 5-HT2A Receptor
Mol. Pharmacol., November 1, 2007; 72(5): 1200 - 1209.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
E. M. Adkins, E. L. Barker, and R. D. Blakely
Interactions of Tryptamine Derivatives with Serotonin Transporter Species Variants Implicate Transmembrane Domain I in Substrate Recognition
Mol. Pharmacol., March 1, 2001; 59(3): 514 - 523.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
D. A. Shapiro, K. Kristiansen, W. K. Kroeze, and B. L. Roth
Differential Modes of Agonist Binding to 5-Hydroxytryptamine2A Serotonin Receptors Revealed by Mutation and Molecular Modeling of Conserved Residues in Transmembrane Region 5
Mol. Pharmacol., November 1, 2000; 58(5): 877 - 886.
[Abstract] [Full Text]


Home page
NeuroscientistHome page
B. L. Roth, D. L. Willins, K. Kristiansen, and W. K. Kroeze
Activation is Hallucinogenic and Antagonism is Therapeutic: Role of 5-HT2A Receptors in Atypical Antipsychotic Drug Actions
Neuroscientist, July 1, 1999; 5(4): 254 - 262.
[Abstract] [PDF]


Home page
Mol. Pharmacol.Home page
T. Wurch, F. C. Colpaert, and P. J. Pauwels
Chimeric Receptor Analysis of the Ketanserin Binding Site in the Human 5-Hydroxytryptamine1D Receptor: Importance of the Second Extracellular Loop and Fifth Transmembrane Domain in Antagonist Binding
Mol. Pharmacol., December 1, 1998; 54(6): 1088 - 1096.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
F. G. Boess, F. J. Monsma Jr., V. Meyer, C. Zwingelstein, and A. J. Sleight
Interaction of Tryptamine and Ergoline Compounds with Threonine 196 in the Ligand Binding Site of the 5-Hydroxytryptamine6 Receptor
Mol. Pharmacol., September 1, 1997; 52(3): 515 - 523.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
B. L. Roth, M. Shoham, M. S. Choudhary, and N. Khan
Identification of Conserved Aromatic Residues Essential for Agonist Binding and Second Messenger Production at 5-Hydroxytryptamine2A Receptors
Mol. Pharmacol., August 1, 1997; 52(2): 259 - 266.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
B. L. Roth, M. S. Choudhary, N. Khan, and A. Z. Uluer
High-affinity Agonist Binding Is Not Sufficient for Agonist Efficacy at 5-Hydroxytryptamine2A Receptors: Evidence in Favor of a Modified Ternary Complex Model
J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 576 - 583.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
N. Almaula, B. J. Ebersole, D. Zhang, H. Weinstein, and S. C. Sealfon
Mapping the Binding Site Pocket of the Serotonin 5-Hydroxytryptamine2A Receptor. Ser3.36(159) PROVIDES A SECOND INTERACTION SITE FOR THE PROTONATED AMINE OF SEROTONIN BUT NOT OF LYSERGIC ACID DIETHYLAMIDE OR BUFOTENIN
J. Biol. Chem., June 21, 1996; 271(25): 14672 - 14675.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1994 by the American Society for Pharmacology and Experimental Therapeutics